Treatment of locally recurrent nasopharyngeal carcinoma with Camrelizumab combined with chemoradiotherapy: a prospective, randomized, controlled phase II clinical study
Latest Information Update: 02 Dec 2020
Price :
$35 *
At a glance
- Drugs Camrelizumab (Primary) ; Antineoplastics
- Indications Carcinoma; Nasopharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 02 Dec 2020 New trial record